Related Experiment Video
Updated: Jun 1, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
[Effects of GIP receptor antagonist for treatment of obesity]
1Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University Graduate School of Medicine.
Abstract:
Glucose-dependent insulinotropic polypeptide(GIP) has been known as a peptide hormone with the effects not only of the augmentation of glucose induced insulin secretion but of the fat accumulation in adipocytes, of the bone formation and of the modulation of brain function. As indicated in GIP receptor deficient experimental animals, GIP receptor antagonists possess favorable effects such as, decreased body adiposity or improvement of glucose intolerance through change of fat metabolism in high-fat diet induced or genetically induced obese experimental animals. This review principally focused on these preclinical data of GIP receptor antagonism.
More Related Videos
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Oral Hypoglycemic Agents: Biguanides and Glitazones
